<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Facts Views Vis Obgyn</journal-id><journal-id journal-id-type="iso-abbrev">Facts Views Vis Obgyn</journal-id><journal-id journal-id-type="pmc">PMC4788335</journal-id><journal-title-group><journal-title>Facts, Views &#x00026; Vision in ObGyn</journal-title></journal-title-group><issn pub-type="ppub">2032-0418</issn><publisher><publisher-name>Universa Press</publisher-name><publisher-loc>Wetteren, Belgium</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27729970</article-id><article-id pub-id-type="pmc">5058414</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Improving systemic breast cancer therapy: time to look beyond the primary tumour?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Vandendriessche</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Van De Putte</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Van Den Broecke</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>De Jonge</surname><given-names>ETM</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><aff id="aff1">Department of Obstetrics &#x00026; Gynaecology, Ziekenhuis Oost-Limburg Campus St. Jan, Schiepse Bos 6, 3600 Genk, Belgium.</aff><aff id="aff2">Department of Obstetrics &#x00026; Gynaecology, University Hospital Ghent, De Pintelaan 185, 9000 Gent, Belgium.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence at: <email>eric.dejonge@zol.be</email></corresp></author-notes><pub-date date-type="pub" publication-format="print" iso-8601-date="2015-12-28"><day>28</day><month>12</month><year>2015</year></pub-date><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2016-01-12"><day>12</day><month>1</month><year>2016</year></pub-date><volume>7</volume><issue>4</issue><fpage>251</fpage><lpage>256</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Facts, Views &#x00026; Vision</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract abstract-type="section"><sec><title>Aim</title><p>Intra and inter tumour heterogeneity is a known feature in cancer because tumour cells undergo changes at genetic and epigenetic level as they spread from their primary tumour site. Adjuvant treatment protocols in breast cancer are currently based on the biological characteristics of the primary tumour, which in most cases has been removed surgically. Considering tumour heterogeneity in metastases we examined the present status of knowledge regarding measurable differences in tumour profiling between the primary breast tumour and its synchronous axillary lymph node metastases (ALNM) and if so whether adjuvant therapy directed towards the tumour characteristics of the ALNM instead of those of the primary tumour is more effective.</p></sec><sec><title>Methods</title><p>We performed a literature search in Pubmed with the following MeSH headings: HUMAN and BREAST NEOPLASMS and RECEPTORS and ErbB-2.</p></sec><sec><title>Results</title><p>A significant change in tumour features was seen in metachronous metastases. In contrast, a high concordance of biomarker expression was reported between a primary breast tumour and its synchronous ALNM.</p></sec><sec><title>Conclusion</title><p>Tumour heterogeneity is a challenge for targeted therapy. A poor response can be explained by the diversity of tumour cells. The biological profile of synchronous ALNM measured by oestrogen (ER), progesterone (PR) and her-2-neu receptor status does not differ from the primary breast tumour and is not predictive of the tumour profile in metachronous metastasis. New techniques, such as profiling of circulating tumour cells or tumour behaviour in xenografts, are promising in directing more effective adjuvant therapy.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Biomarker</kwd><kwd>breast cancer</kwd><kwd>breast neoplasms</kwd><kwd>metastases</kwd><kwd>oestrogen receptors</kwd><kwd>progesterone receptors</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Breast cancer remains the most common cancer in women worldwide and rated second in cancer related mortality (<xref rid="B33" ref-type="bibr">World Cancer Report, 2014</xref>). Breast cancer treatment strategies and prognosis are guided by classification into molecular subtypes as there are: Luminal A, Luminal B, her-2-neu positive and triple negative/basal-like tumours. Surgery remains the primary treatment in most cases and entails the complete removal of the primary tumour in the breast and a surgical staging of the axilla. Adjuvant treatment is dictated by stage of disease, type of surgery and the molecular subtype of the primary tumour (<xref rid="B18" ref-type="bibr">Goldhirsch et al., 2013</xref>).</p><p>Our understanding of carcinogenesis was driven by the observation that a tumour consists of cell groups (clones) with molecular and phenotypic differences. This phenomenon is known as tumour heterogeneity and is caused by differences in susceptibility for genetic mutations, epigenetic alterations and differences in tumour microenvironment (<xref rid="B5" ref-type="bibr">Banerjee, 2010</xref>; <xref rid="B16" ref-type="bibr">Gerlinger et al., 2012</xref>; <xref rid="B30" ref-type="bibr">Swanton, 2012</xref>). Tumour heterogeneity constitutes a challenge for cancer research and treatment. The immediate implication of intra tumour heterogeneity is that a specific clone of tumour cells as a result of its aggressive biological behaviour might be responsible for the ultimate outcome of the patient whilst it remains unrecognized by the tumour profiling techniques available at present. Inter tumour heterogeneity on the other hand implicates a change in characteristics between the primary tumour and its metastases. This potentially involves changes in drug sensitivity/resistance (<xref rid="B30" ref-type="bibr">Swanton, 2012</xref>).</p><p>Whilst developing more advanced tumour profiling techniques and clinically useful biomarkers to target therapy one wonders whether it would not be more effective in case of lymph node positive breast cancer (LNPBC) to direct adjuvant therapy towards the nature of the ALNM rather than that of the primary breast tumour removed by surgery. In order to explore this hypothesis we searched the literature for data on inter tumour heterogeneity in LNPBC.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><label>2.1</label><title>Types of studies</title><p>Breast cancer studies reporting on the expression of ER or PR or her-2-neu in primary breast tumour and its metastases (synchronous and/or metachronous) were included. Both prospective and retrospective studies were included.</p><p>A comprehensive search was performed in Pubmed, articles published from 2000 until 2015, selected by 3 readers (EVD, GVDP, EDJ). The following MeSH headings were used: HUMAN and BREAST NEOPLASMS and RECEPTORS and ErbB-2. Only full text articles written in English were selected (<xref ref-type="fig" rid="g001">Fig. 1</xref>).</p><fig id="g001" orientation="landscape" position="float"><label>Figure 1</label><caption><p>&#x02014; Search strategy</p></caption><graphic xlink:href="FVVinObGyn-7-251-g001"/></fig></sec><sec id="s2b" sec-type="subjects"><label>2.2</label><title>Subjects</title><p>All women included in this analysis had a histological diagnosis of primary breast cancer and ipsilateral, synchronous ALNM. If studied, pathological information on possible asynchronous, distant metastasis was processed as well. No inclusion restrictions were retained regarding age, menopausal stage or type of treatment.</p></sec><sec id="s2c"><label>2.3</label><title>Types of outcome measurements</title><p>Hormone receptor analysis in the studies included was performed by immunohistochemistry, in which positive interpretation requires at least 1% of tumour cells showing positive nuclear staining of any intensity. Her-2-neu status was tested with two possible methods: immunohistochemistry and/or fluorescence in situ hybridization. Tumour heterogeneity was interpreted as a difference in expression of biomarkers.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>A summary of articles reporting on breast cancer and the concordance regarding ER, PR and her-2-neu expression between the primary breast tumour and synchronous or metachronous metastases is shown in Tables <xref ref-type="table" rid="T1">I</xref> and <xref ref-type="table" rid="T2">II</xref>. The majority of studies are retrospective, consists of small numbers of women and in most studies a central pathology review was performed. In general there is a shift in the ER/PR/her-2-neu profile in 10-20 % of synchronous ALNM and 20-40% of metachronous metastases. Both losses and/or gain of receptor expression were noticed. In metachronous metastases loss of receptor expression was more pronounced. Loss of ER, PR and/or her-2-neu expression occurred in 25%, 33% and 8% of cases respectively in these combined series, whilst gain of receptor expression was seen in 8%, 8% and 12% of cases respectively (<xref rid="B28" ref-type="bibr">Simmons et al., 2009</xref>; <xref rid="B20" ref-type="bibr">Hoefnagel et al., 2010</xref>; <xref rid="B23" ref-type="bibr">Jensen et al., 2012</xref>; <xref rid="B24" ref-type="bibr">Lindstr&#x000f6;m et al., 2012</xref>; <xref rid="B21" ref-type="bibr">Ibrahim et al., 2013</xref>).</p><table-wrap id="T1" orientation="landscape" position="float"><label>Table I</label><caption><p>&#x02014; ER, PR, and her-2-neu expression profiles: concordance (%) between the primary breast tumour and synchronous LNM.</p></caption><table frame="hsides" rules="groups" style="border-collapse: collapse"><thead><tr style="border-top: solid"><td rowspan="2" style="border-right: solid" colspan="1"><bold>Author</bold></td><td rowspan="2" style="border-right: solid" colspan="1"><bold>Study structure</bold></td><td rowspan="2" style="border-right: solid" colspan="1"><bold>Number of patients</bold></td><td colspan="3" rowspan="1"><bold>Biomarker</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>ER</bold></td><td rowspan="1" colspan="1"><bold>PR</bold></td><td rowspan="1" colspan="1"><bold>her-2-neu</bold></td></tr></thead><tbody><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B14" ref-type="bibr">Falck 2010</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Retrospective<break/>pT1-2 N1M0</td><td style="border-right: solid" rowspan="1" colspan="1">425</td><td style="border-right: solid" rowspan="1" colspan="1">93%</td><td style="border-right: solid" rowspan="1" colspan="1">84%</td><td style="border-right: solid" rowspan="1" colspan="1">97%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B11" ref-type="bibr">D&#x02019;Andrea 2007</xref></td><td style="border-right: solid" rowspan="1" colspan="1"> Retrospective<break/>LNPBC<break/>(&#x0003e; 10 positive LN, M0)</td><td style="border-right: solid" rowspan="1" colspan="1">90</td><td style="border-right: solid" rowspan="1" colspan="1">96.6%</td><td style="border-right: solid" rowspan="1" colspan="1">96.6%</td><td style="border-right: solid" rowspan="1" colspan="1">96.1%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B22" ref-type="bibr">Ieni 2014</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Retrospective<break/>LNPBC (M0)</td><td style="border-right: solid" rowspan="1" colspan="1">148</td><td style="border-right: solid" rowspan="1" colspan="1">-</td><td style="border-right: solid" rowspan="1" colspan="1">-</td><td style="border-right: solid" rowspan="1" colspan="1">95.3%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B2" ref-type="bibr">Aitken 2010</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Retrospective<break/>High grade LNPBC (M0)</td><td style="border-right: solid" rowspan="1" colspan="1">385</td><td style="border-right: solid" rowspan="1" colspan="1">71.6%</td><td style="border-right: solid" rowspan="1" colspan="1">76.5%</td><td style="border-right: solid" rowspan="1" colspan="1">91.1%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B1" ref-type="bibr">Adamczyk 2012</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Retrospective<break/>T1-3 N1M0</td><td style="border-right: solid" rowspan="1" colspan="1">108</td><td style="border-right: solid" rowspan="1" colspan="1">96.5%</td><td style="border-right: solid" rowspan="1" colspan="1">97.6%</td><td style="border-right: solid" rowspan="1" colspan="1">95.5%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B19" ref-type="bibr">Greer 2012</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Prospective<break/>LNP(macro)BC</td><td style="border-right: solid" rowspan="1" colspan="1">165</td><td style="border-right: solid" rowspan="1" colspan="1">83%</td><td style="border-right: solid" rowspan="1" colspan="1">97%</td><td style="border-right: solid" rowspan="1" colspan="1">97%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B23" ref-type="bibr">Jensen 2012</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Retrospective</td><td style="border-right: solid" rowspan="1" colspan="1">53</td><td style="border-right: solid" rowspan="1" colspan="1">96%</td><td style="border-right: solid" rowspan="1" colspan="1">-</td><td style="border-right: solid" rowspan="1" colspan="1">100%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B9" ref-type="bibr">Carlsson 2004</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Retrospective<break/>M+</td><td style="border-right: solid" rowspan="1" colspan="1">47</td><td style="border-right: solid" rowspan="1" colspan="1">-</td><td style="border-right: solid" rowspan="1" colspan="1">-</td><td style="border-right: solid" rowspan="1" colspan="1">100%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B4" ref-type="bibr">Ataseven 2012</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Prospective<break/>LNPBC</td><td style="border-right: solid" rowspan="1" colspan="1">119</td><td style="border-right: solid" rowspan="1" colspan="1">97.4%</td><td style="border-right: solid" rowspan="1" colspan="1">96.6%</td><td style="border-right: solid" rowspan="1" colspan="1">96.6%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B7" ref-type="bibr">Briffod 2000</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Fine needle aspiration cytology<break/>LNPBC</td><td style="border-right: solid" rowspan="1" colspan="1">38</td><td style="border-right: solid" rowspan="1" colspan="1">94.7%</td><td style="border-right: solid" rowspan="1" colspan="1">86.8%</td><td style="border-right: solid" rowspan="1" colspan="1">92%</td></tr><tr style="border-top: solid; border-bottom: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B3" ref-type="bibr">Aoyama 2010</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Retrospective<break/>LNPBC</td><td style="border-right: solid" rowspan="1" colspan="1">60</td><td style="border-right: solid" rowspan="1" colspan="1">-</td><td style="border-right: solid" rowspan="1" colspan="1">-</td><td style="border-right: solid" rowspan="1" colspan="1">91.6%</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="landscape" position="float"><label>Table II</label><caption><p>&#x02014; ER, PR, and her-2-neu expression profiles: concordance (%) between the primary breast tumour and metachronous metastasis.</p></caption><table frame="hsides" rules="groups" style="border-collapse: collapse"><thead><tr style="border-top: solid"><td rowspan="2" style="border-right: solid" colspan="1"><bold>Author</bold></td><td rowspan="2" style="border-right: solid" colspan="1"><bold>Study structure</bold></td><td rowspan="2" style="border-right: solid" colspan="1"><bold>Number of patients</bold></td><td colspan="3" rowspan="1"><bold>Biomarker</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>ER</bold></td><td rowspan="1" colspan="1"><bold>PR</bold></td><td rowspan="1" colspan="1"><bold>her-2-neu</bold></td></tr></thead><tbody><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B21" ref-type="bibr">Ibrahim 2013</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Retrospective</td><td style="border-right: solid" rowspan="1" colspan="1">120</td><td style="border-right: solid" rowspan="1" colspan="1">83.6%</td><td style="border-right: solid" rowspan="1" colspan="1">58.3%</td><td style="border-right: solid" rowspan="1" colspan="1">82.5%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B20" ref-type="bibr">Hoefnagel 2010</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Retrospective</td><td style="border-right: solid" rowspan="1" colspan="1">233</td><td style="border-right: solid" rowspan="1" colspan="1">89.7%</td><td style="border-right: solid" rowspan="1" colspan="1">70%</td><td style="border-right: solid" rowspan="1" colspan="1">94.8%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B24" ref-type="bibr">Lindstr&#x000f6;m 2012</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Retrospective</td><td style="border-right: solid" rowspan="1" colspan="1">1010</td><td style="border-right: solid" rowspan="1" colspan="1">66.4%</td><td style="border-right: solid" rowspan="1" colspan="1">68%</td><td style="border-right: solid" rowspan="1" colspan="1">84.3%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B23" ref-type="bibr">Jensen 2012</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Prospective</td><td style="border-right: solid" rowspan="1" colspan="1">119</td><td style="border-right: solid" rowspan="1" colspan="1">88%</td><td style="border-right: solid" rowspan="1" colspan="1">-</td><td style="border-right: solid" rowspan="1" colspan="1">91%</td></tr><tr style="border-top: solid"><td style="border-right: solid" rowspan="1" colspan="1"><xref rid="B28" ref-type="bibr">Simmons 2009</xref></td><td style="border-right: solid" rowspan="1" colspan="1">Prospective</td><td style="border-right: solid" rowspan="1" colspan="1">25</td><td style="border-right: solid" rowspan="1" colspan="1">60%</td><td style="border-right: solid" rowspan="1" colspan="1">60%</td><td style="border-right: solid" rowspan="1" colspan="1">92%</td></tr></tbody></table></table-wrap></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In this review of the literature we studied the reported changes in biological profile between the primary breast tumour and its metastases at the level of ER, PR and her-2-neu expression as biomarkers which to date are used in daily clinical practice to guide systemic adjuvant therapy in breast cancer. In general there was no significant change seen in biomarker profile between the primary breast tumour and its synchronous ALNM (<xref rid="B9" ref-type="bibr">Carlsson et al., 2004</xref>; D&#x02019; Andrea et al., 2007; <xref rid="B14" ref-type="bibr">Falck et al., 2010</xref>; <xref rid="B1" ref-type="bibr">Adamczyk et al., 2012</xref>; <xref rid="B4" ref-type="bibr">Ataseven et al., 2012</xref>; <xref rid="B19" ref-type="bibr">Greer et al., 2012</xref>; <xref rid="B23" ref-type="bibr">Jensen et al., 2012</xref>; <xref rid="B22" ref-type="bibr">Ieni et al., 2014</xref>). The results of <xref rid="B2" ref-type="bibr">Aitken et al. (2010)</xref> are in contrast to the concordance rates mentioned earlier as they found a disparate breast/node status for at least one biomarker (ER of PR) in almost 50% of cases, resulting in ALNM with worse prognostic profile illustrated by shifts to ER negativity and her-2-neu positivity. A study population consisting of highgrade primary breast tumours only is a possible explanation for these aberrant results. Systematic evaluation of these biomarkers in ALNM therefore is not recommended. On the contrary inter tumour heterogeneity between primary tumours of the breast and distant metachronous metastases are responsible for a significant change of tumour features (Table II). In the event of metachronous disease, the biomarker status of this new locus should be reassessed to optimize adjuvant therapy in order to improve patient outcome. Detection of loss of function in this new tumour locus reflected in a change/loss of an immunohistochemical biomarker should avoid ineffective therapy based on the biomarker signature of the primary breast tumour and direct therapy into different treatment strategies of proven efficacy.</p><p>Removal of involved lymph nodes is no longer believed to improve prognosis in breast cancer although their presence remains an important negative prognostic factor for relapse and death in breast cancer (<xref rid="B17" ref-type="bibr">Giuliano et al., 2011</xref>; <xref rid="B13" ref-type="bibr">Falck et al., 2013</xref>). It remains uncertain which role the tumour cells colonizing synchronous ALNM play in the mechanism of dissemination to organs at distance. Do tumour cells disseminate to distant organs via synchronous ALNM or does lymphogenic and hematogenic spread operate through different mechanisms? Tumour cells designed to metastasize hematogenously seem to be biologically different from the tumour cells found in ALNM (<xref rid="B31" ref-type="bibr">van de Vijver et al., 2002</xref>).</p><p><xref rid="B15" ref-type="bibr">Fidler (2003)</xref> revisited the &#x02018;seed and soil&#x02019; hypothesis describing the process of metastasis and explaining why specific tumour types (the &#x02018;seed&#x02019;) spread to specific organs (the &#x02018;soil&#x02019;). It is clear now that throughout the process of tumour progression cells acquire genetic variations and instability, which determines whether their phenotype predisposes to dissemination. In the event of dissemination, the locus of metastasis is not random and not only depending on anatomical barriers. The microenvironment of each organ is different. Different cell surface receptors and variable growth factors are responsible for a tumour cell specific and host specific response. This revisited &#x02018;seed and soil&#x02019; hypothesis explains why tumour cells emerging in synchronous ALNM have a phenotype different from those in metachronous metastases. The reason for high concordance in biomarker expression between the primary breast tumour and the synchronous ALNM is less clear: the migration of tumour cells to the axilla is either based on a different mechanism than the one that dictates dissemination to distant loci. Therefore other biomarkers remaining unrevealed to date may differentiate between tumour cells present in the primary breast tumour and the synchronous ALNM.</p><p>However to date no studies have been conducted examining differences in outcome of breast cancer therapy comparing systemic therapy directed against the biomarker expression in synchronous ALNM versus the biomarker expression in primary breast tumour.</p><p>To interfere with disease progression targets other than tumour cells in synchronous ALNM could be explored: the xenograft model to study tumour behaviour in the laboratory, molecular imaging with biomarkers to locate and bio-type metastatic tumour and the concept of circulating tumour cells to improve therapy in an early stage of disease.</p><p>An in vivo mouse-hosted patient derived xenograft (PDX) is likely to reflect tumour biology better than in vitro cell lines derived from tumours. The study of tumour behaviour and tumour heterogeneity should be more accurate in PDX. It is a promising model for basic research in oncology and phase I interventional studies with new compounds (<xref rid="B32" ref-type="bibr">Willey et al., 2015</xref>). For instance tumour grafting in the mammary glands of mice gives rise to metastasis with patterns similar to those observed in the original breast cancer patients (<xref rid="B12" ref-type="bibr">DeRose et al., 2011</xref>). Likewise, aurora kinase inhibitor, a cell-cycle regulator, was tested in triple negative breast cancer xenografts to study its potential as a new anticancer drug (<xref rid="B27" ref-type="bibr">Romanelli et al., 2012</xref>).</p><p>Non-invasive assessment of receptor status by molecular imaging via PET or SPECT whether or not combined with CT or MRI may become a way of identifying therapeutic anchors in the individual patient. Developing isotopic marked target molecules against ER, PR, her-2-neu or other clinically useful molecular targets (radiopharmaceuticals) could reveal receptor status of tumour sites in particular tumour deposits not amenable for biopsy. Biomarker specific targeting agents are labelled with positron or gamma-emitting radionuclides, optical dyes or paramagnetic contrast molecules for PET, SPECT and MRI respectively (<xref rid="B8" ref-type="bibr">Capala and Bouchelouche, 2010</xref>; <xref rid="B29" ref-type="bibr">S&#x000f6;rensen et al., 2014</xref>).</p><p>The phenomenon of circulating tumour cells (CTCs) was described as early as in the 1800&#x02019;s (<xref rid="B26" ref-type="bibr">Recamier, 1829</xref>).</p><p><xref rid="B10" ref-type="bibr">Cristofanilli et al. (2004)</xref> tested the hypothesis that levels of CTCs can predict survival in metastatic breast cancer and concluded that the number of CTCs before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer. Detection, quantification and characterization of CTCs open new perspectives on cancer dissemination and treatment. In the current staging of breast cancer the finding of CTCs is referred to as a stage cM0 (i+). Studies on CTCs and breast cancer are in phase 3, offering major perspectives for both biological and clinical research on the metastatic process (<xref rid="B6" ref-type="bibr">Bidard et al., 2013</xref>). Hypothetically CTCs could be a marker of &#x02018;active&#x02019; disease and a precursor of metastatic disease. Biomarker expression in CTCs was described by <xref rid="B25" ref-type="bibr">Mikulov&#x000e1; et al. (2014)</xref>. They were able to detect CTCs in 31% of 54 patients with early stage breast cancer and found a 20% discordance in her-2-neu expression between primary breast tumour and CTCs.</p><p>In conclusion, tumour heterogeneity constitutes a challenge for cancer research and therapy. We reviewed the data on the ER, PR and her-2-neu expression both in the primary breast tumour and its synchronous ALNM and metachronous metastases as the most used biomarkers in breast cancer in daily clinical practice to date. A high concordance between primary breast tumour and synchronous ALNM was seen. Therefore determination of ER, PR, her-2-neu on synchronous ALNM to tune systemic therapy and therefore outcome is not contributing. Since tumour heterogeneity between the primary breast tumour and metachronous metastasis is ascertained, distant metastasis should be biopsied and their biomarker profile direct therapeutic planning. The process of dissemination of tumour cells and implications for cancer treatment however remains unclear. To date we know that ALNM in breast cancer are important for prognosis, their removal does not impact on survival and their biological profile does not predict the biological characteristics of metachronous metastasis. Both the exploration of new biomarkers in ALNM and the biological profile of CTCs therefore could be the next step in our understanding of inter tumour heterogeneity and its therapeutic consequences.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Adamczyk</surname><given-names>A</given-names></name><name><surname>Niemiec</surname><given-names>J</given-names></name><name><surname>Ambicka</surname><given-names>A</given-names></name><etal/></person-group><article-title>Expression of ER/PR/HER2, basal markers and adhesion molecules in primary breast cancer and in lymph nodes metastases: a comparative immunohistochemical analysis.</article-title><source>Pol J Pathol</source><year>2012</year><volume>63</volume><issue>4</issue><fpage>228</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">23359191</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Aitken</surname><given-names>SJ</given-names></name><name><surname>Thomas</surname><given-names>JS</given-names></name><name><surname>Langdon</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases.</article-title><source>Ann Oncol</source><year>2010</year><volume>21</volume><issue>6</issue><fpage>1254</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdp427</pub-id><pub-id pub-id-type="pmid">19858088</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Aoyama</surname><given-names>K</given-names></name><name><surname>Kamio</surname><given-names>T</given-names></name><name><surname>Nishikawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.</article-title><source>Jpn J Clin Oncol</source><year>2010</year><volume>40</volume><issue>7</issue><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyq019</pub-id><pub-id pub-id-type="pmid">20202990</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Ataseven</surname><given-names>B</given-names></name><name><surname>Gologan</surname><given-names>D</given-names></name><name><surname>Gunesch</surname><given-names>A</given-names></name><etal/></person-group><article-title>HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics.</article-title><source>Breast Care (Basel)</source><year>2012</year><volume>7</volume><issue>6</issue><fpage>465</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1159/000345467</pub-id><pub-id pub-id-type="pmid">24715828</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>D</given-names></name></person-group><article-title>Reinventing diagnostics for personalized therapy in oncology.</article-title><source>Cancers (Basel)</source><year>2010</year><volume>2</volume><issue>2</issue><fpage>1066</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.3390/cancers2021066</pub-id><pub-id pub-id-type="pmid">24281107</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Bidard</surname><given-names>FC</given-names></name><name><surname>Fehm</surname><given-names>T</given-names></name><name><surname>Ignatiadis</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials.</article-title><source>Cancer Metastasis Rev</source><year>2013</year><volume>32</volume><issue>1</issue><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1007/s10555-012-9398-0</pub-id><pub-id pub-id-type="pmid">23129208</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Briffod</surname><given-names>M</given-names></name><name><surname>Hacene</surname><given-names>K</given-names></name><name><surname>Le Doussal</surname><given-names>V</given-names></name><etal/></person-group><article-title>Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases.</article-title><source>Mod Pathol.</source><year>2000</year><volume>13</volume><issue>8</issue><fpage>841</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1038/modpathol.3880149</pub-id><pub-id pub-id-type="pmid">10955449</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Capala</surname><given-names>J</given-names></name><name><surname>Bouchelouche</surname><given-names>K</given-names></name></person-group><article-title>Molecular imaging of HER2-positive breast cancer: a step toward an individualized &#x02018;image and treat&#x02019; strategy.</article-title><source>Curr Opin Oncol</source><year>2010</year><volume>22</volume><issue>6</issue><fpage>559</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1097/CCO.0b013e32833f8c3a</pub-id><pub-id pub-id-type="pmid">20842031</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>J</given-names></name><name><surname>Nordgren</surname><given-names>H</given-names></name><name><surname>Sj&#x000f6;str&#x000f6;m</surname><given-names>J</given-names></name></person-group><article-title>HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review.</article-title><source>Br J Cancer</source><year>2004</year><volume>90</volume><issue>12</issue><fpage>2344</fpage><lpage>2348</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6601881</pub-id><pub-id pub-id-type="pmid">15150568</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Cristofanilli</surname><given-names>M</given-names></name><name><surname>Budd</surname><given-names>GT</given-names></name><name><surname>Ellis</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Circulating tumor cells, disease progression, and survival in metastatic breast cancer.</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><issue>8</issue><fpage>781</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa040766</pub-id><pub-id pub-id-type="pmid">15317891</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>D&#x02019;Andrea</surname><given-names>MR</given-names></name><name><surname>Limiti</surname><given-names>MR</given-names></name><name><surname>Bari</surname><given-names>M</given-names></name><etal/></person-group><article-title>Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.</article-title><source>Breast Cancer Res Treat</source><year>2007</year><volume>101</volume><issue>3</issue><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1007/s10549-006-9300-2</pub-id><pub-id pub-id-type="pmid">16835704</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>DeRose</surname><given-names>YS</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>Y-C</given-names></name><etal/></person-group><article-title>Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes.</article-title><source>Nat Med</source><year>2011</year><fpage>1514</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1038/nm.2454</pub-id><pub-id pub-id-type="pmid">22019887</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Falck</surname><given-names>AK</given-names></name><name><surname>Bendahl</surname><given-names>PO</given-names></name><name><surname>Chebil</surname><given-names>G</given-names></name><etal/></person-group><article-title>Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years&#x02019; follow-up.</article-title><source>Breast Cancer Res Treat</source><year>2013</year><volume>140</volume><issue>1</issue><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1007/s10549-013-2617-8</pub-id><pub-id pub-id-type="pmid">23807420</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Falck</surname><given-names>AK</given-names></name><name><surname>Fern&#x000f6;</surname><given-names>M</given-names></name><name><surname>Bendahl</surname><given-names>PO</given-names></name><etal/></person-group><article-title>Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?</article-title><source>World J Surg</source><year>2010</year><volume>34</volume><issue>7</issue><fpage>1434</fpage><lpage>1441</lpage><pub-id pub-id-type="doi">10.1007/s00268-010-0499-z</pub-id><pub-id pub-id-type="pmid">20213203</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Fidler</surname><given-names>IJ</given-names></name></person-group><article-title>The pathogenesis of cancer metastasis: the &#x02018;seed and soil&#x02019; hypothesis revisited.</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><issue>6</issue><fpage>453</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/nrc1098</pub-id><pub-id pub-id-type="pmid">12778135</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Gerlinger</surname><given-names>M</given-names></name><name><surname>Rowan</surname><given-names>AJ</given-names></name><name><surname>Horswell</surname><given-names>S</given-names></name><etal/></person-group><article-title>Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>10</issue><fpage>883</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1113205</pub-id><pub-id pub-id-type="pmid">22397650</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Giuliano</surname><given-names>ae</given-names></name><name><surname>Hunt</surname><given-names>KK</given-names></name><name><surname>Ballman</surname><given-names>KV</given-names></name><etal/></person-group><article-title>Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.</article-title><source>JAMA</source><year>2011</year><volume>305</volume><issue>6</issue><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1001/jama.2011.90</pub-id><pub-id pub-id-type="pmid">21304082</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><name><surname>Coates</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><issue>9</issue><fpage>2206</fpage><lpage>2223</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdt303</pub-id><pub-id pub-id-type="pmid">23917950</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Greer</surname><given-names>LT</given-names></name><name><surname>Balayla</surname><given-names>J</given-names></name><name><surname>Garcia-Velasco</surname><given-names>JA</given-names></name></person-group><article-title>Should immunohistochemical (IHC) markers be performed on axillary lymph node metastases in view of the lack of concordance between the primary tumor and axillary lymph node metastases?</article-title><source>J Am Coll Surg</source><year>2012</year><volume>215</volume><issue>3</issue><elocation-id/></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Hoefnagel</surname><given-names>LD</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>van Slooten</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Receptor conversion in distant breast cancer metastases.</article-title><source>Breast Cancer Res</source><year>2010</year><volume>12</volume><issue>5</issue><elocation-id/><pub-id pub-id-type="doi">10.1186/bcr2645</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>T</given-names></name><name><surname>Farolfi</surname><given-names>A</given-names></name><name><surname>Scarpi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.</article-title><source>Oncology</source><year>2013</year><volume>84</volume><issue>3</issue><fpage>150</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1159/000345795</pub-id><pub-id pub-id-type="pmid">23257904</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Ieni</surname><given-names>A</given-names></name><name><surname>Barresi</surname><given-names>V</given-names></name><name><surname>Caltabiano</surname><given-names>R</given-names></name><etal/></person-group><article-title>Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation.</article-title><source>Onco Targets Ther</source><year>2014</year><volume>7</volume><fpage>1267</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.2147/OTT.S65294</pub-id><pub-id pub-id-type="pmid">25050068</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>JD</given-names></name><name><surname>Knoop</surname><given-names>A</given-names></name><name><surname>Ewertz</surname><given-names>M</given-names></name><etal/></person-group><article-title>ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.</article-title><source>Breast Cancer Res Treat</source><year>2012</year><volume>132</volume><issue>2</issue><fpage>511</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1007/s10549-011-1610-3</pub-id><pub-id pub-id-type="pmid">21667123</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Lindstr&#x000f6;m</surname><given-names>LS</given-names></name><name><surname>Karlsson</surname><given-names>E</given-names></name><name><surname>Wilking</surname><given-names>UM</given-names></name><etal/></person-group><article-title>Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><issue>21</issue><fpage>2601</fpage><lpage>2608</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.37.2482</pub-id><pub-id pub-id-type="pmid">22711854</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Mikulov&#x000e1;</surname><given-names>V</given-names></name><name><surname>Cabi&#x00148;akov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Janatkov&#x000e1;</surname><given-names>I</given-names></name><etal/></person-group><article-title>Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.</article-title><source>Scand J Clin Lab Invest</source><year>2014</year><volume>74</volume><issue>2</issue><fpage>132</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.3109/00365513.2013.864784</pub-id><pub-id pub-id-type="pmid">24350991</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Recamier</surname><given-names>JC</given-names></name></person-group><article-title>L&#x02019;histoire de le Meme Maladie.</article-title><source>Gabor</source><year>1829</year><fpage>110</fpage><pub-id pub-id-type="doi">10.1016/j.rbmo.2012.06.012</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Romanelli</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>A</given-names></name><name><surname>Assayag</surname><given-names>F</given-names></name><etal/></person-group><article-title>Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triplenegative breast cancer xenografts.</article-title><source>Mol Cancer Ther</source><year>2012</year><volume>11</volume><issue>12</issue><fpage>2693</fpage><lpage>2703</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0441-T</pub-id><pub-id pub-id-type="pmid">23012245</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>N</given-names></name><name><surname>Geddie</surname><given-names>W</given-names></name><etal/></person-group><article-title>Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?</article-title><source>Ann Oncol</source><year>2009</year><volume>20</volume><issue>9</issue><fpage>1499</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1007/s00404-013-3020-8</pub-id><pub-id pub-id-type="pmid">19299408</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>S&#x000f6;rensen</surname><given-names>J</given-names></name><name><surname>Sandberg</surname><given-names>D</given-names></name><name><surname>Sandstr&#x000f6;m</surname><given-names>M</given-names></name><etal/></person-group><article-title>First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.</article-title><source>J Nucl Med</source><year>2014</year><volume>55</volume><issue>5</issue><fpage>730</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.2967/jnumed.113.131243</pub-id><pub-id pub-id-type="pmid">24665085</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Swanton</surname><given-names>C</given-names></name></person-group><article-title>Intratumor heterogeneity: evolution through space and time.</article-title><source>Cancer Res</source><year>2012</year><volume>72</volume><issue>19</issue><fpage>4875</fpage><lpage>4882</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2217</pub-id><pub-id pub-id-type="pmid">23002210</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>van't Veer</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>A gene-expression signature as a predictor of survival in breast cancer.</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><issue>25</issue><fpage>1999</fpage><lpage>2009</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021967</pub-id><pub-id pub-id-type="pmid">12490681</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Willey</surname><given-names>CD</given-names></name><name><surname>Gilvert</surname><given-names>AN</given-names></name><name><surname>Anderson</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Patient-Derived Xenografts as a Model System for Radiation Research.</article-title><source>Semin Radiat Oncol</source><year>2015</year><volume>25</volume><issue>4</issue><fpage>273</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.semradonc.2015.05.008</pub-id><pub-id pub-id-type="pmid">26384275</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="editor"><name><surname>Stewart</surname><given-names>BW</given-names></name><name><surname>Wild</surname><given-names>CP</given-names></name></person-group><article-title>World Cancer Report 2014</article-title><source>World Health Organization</source><year>2014</year><isbn>9789283204299</isbn></element-citation></ref></ref-list></back></article>